The therapeutic value of "Bile Transfer" for complications of acute pancreatitis: A retrospective clinical study

胆汁移植治疗急性胰腺炎并发症的价值:一项回顾性临床研究

阅读:1

Abstract

INTRODUCTION: Acute pancreatitis (AP) is one of the most common gastrointestinal diseases, imposing a significant burden on patients, with its incidence steadily increasing worldwide. Despite a drop in fatality rates, AP-related complications remain high, impacting prognosis. OBJECTIVES: This retrospective clinical study introduces the concept of "bile transfer" (BT) and explores its potential in reducing AP-related complications. METHODS: This single-center, retrospective cohort study evaluated 344 AP patients with gallbladder distension at our hospital from January 2019 to December 2024. Patients were classified into three groups: percutaneous transhepatic gallbladder drainage (PTGD) + bile reinfusion (BT group), PTGD-alone, and conventional treatment to assess complication rates. Logistic regression identified independent risk factors for treatment outcomes. Restricted cubic splines (RCS) were employed to identify optimal indications for BT. RESULTS: Among the 344 patients, the incidence of new complications in the BT group was 21.50 %, significantly lower than in the PTGD-alone (46.59 %) and conventional treatment groups (54.36 %) (p < 0.001). Logistic regression identified Total bilirubin (TBIL), Ca(2+), White blood cell (WBC), and Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) as independent predictors of poor BT outcomes. RCS analysis showed TBIL < 23.6 μmol/L, WBC < 10.6 × 10(9)/L, and Ca(2+)>2.12 mmol/L as optimal indicators for BT use. CONCLUSION: This study introduces BT and shows that PTGD combined with bile reinfusion significantly reduces complications in AP patients. We identified optimal indications and predictors for BT. These findings are clinically important for improving AP patient prognosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。